Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Ann Hematol. 2018 Jun 20. doi: 10.1007/s00277-018-3396-4. [Epub ahead of print]

PMID:
29926156
2.

Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial.

Michels J, Becker N, Suciu S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, Eichmüller SB, Jäger D, Eggermont AMM, Zörnig I.

Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018.

3.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

PMID:
29658430
4.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.

Testori AA, Suciu S, van Akkooi ACJ, Suppa M, Eggermont AMM, de Vries E, Joosse A; European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group.

Melanoma Res. 2018 Jun;28(3):222-229. doi: 10.1097/CMR.0000000000000433.

PMID:
29432281
5.

Attitudes toward mentally ill patients: a comparison between Romanian and international medical students.

Popescu CA, Buzoianu AD, Suciu SM, Armean SM.

Clujul Med. 2017;90(4):401-406. doi: 10.15386/cjmed-776. Epub 2017 Oct 20.

6.

Multimarker Assessment of Diastolic Dysfunction in Metabolic Syndrome Patients.

Mocan M, Anton F, Suciu Ș, Răhăian R, Blaga SN, Fărcaș AD.

Metab Syndr Relat Disord. 2017 Dec;15(10):507-514. doi: 10.1089/met.2017.0060. Epub 2017 Nov 3.

PMID:
29099655
7.

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.

Piette C, Suciu S, Clappier E, Bertrand Y, Drunat S, Girard S, Yakouben K, Plat G, Dastugue N, Mazingue F, Grardel N, van Roy N, Uyttebroeck A, Costa V, Minckes O, Sirvent N, Simon P, Lutz P, Ferster A, Pluchart C, Poirée M, Freycon C, Dresse MF, Millot F, Chantrain C, van der Werff Ten Bosch J, Norga K, Gilotay C, Rohrlich PS, Benoit Y, Cavé H.

Leukemia. 2018 Jan;32(1):244-248. doi: 10.1038/leu.2017.289. Epub 2017 Sep 19. No abstract available.

PMID:
29064485
8.

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, Cameron D, Kotapati S, Chen TT, Wheatley K, Ives N, de Schaetzen G, Efendi A, Buyse M.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx133. Review.

PMID:
28922786
9.

Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.

Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, Yakouben K, Uyttebroeck A, Lutz P, Costa V, Sirvent N, Plouvier E, Munzer M, Poirée M, Minckes O, Millot F, Plantaz D, Maes P, Hoyoux C, Cavé H, Rohrlich P, Bertrand Y, Benoit Y; Children–s Leukemia Group (CLG) of the European Organization for Research and Treatment of Cancer (EORTC).

Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.

10.

Chondroprotective effects of pulsed shortwave therapy in rabbits with experimental osteoarthritis.

Ungur RA, Florea A, Tăbăran AF, Scurtu IC, Onac I, Borda IM, Irsay L, Ciortea VM, Dronca E, Zdrenghea MT, Suciu ŞM.

Rom J Morphol Embryol. 2017;58(2):465-472.

11.

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K; International Melanoma Meta-Analysis Collaborative Group (IMMCG).

Eur J Cancer. 2017 Sep;82:171-183. doi: 10.1016/j.ejca.2017.06.006. Epub 2017 Jul 7. Review.

PMID:
28692949
12.

Corrigendum to "Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy" [Eur J Cancer 67 (2016) 38-45].

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Sacré L, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2017 Sep;82:247. doi: 10.1016/j.ejca.2017.06.001. Epub 2017 Jun 26. No abstract available.

PMID:
28662904
13.

Carbon nanotubes as anti-bacterial agents.

Mocan T, Matea CT, Pop T, Mosteanu O, Buzoianu AD, Suciu S, Puia C, Zdrehus C, Iancu C, Mocan L.

Cell Mol Life Sci. 2017 Oct;74(19):3467-3479. doi: 10.1007/s00018-017-2532-y. Epub 2017 May 23. Review.

PMID:
28536787
14.

Real case of primitive embryonal duodenal carcinoma in a young man.

Barbieux J, Memeo R, De Blasi V, Suciu S, Faucher V, Averous G, Roy C, Marescaux J, Mutter D, Pessaux P.

World J Gastroenterol. 2017 Jan 28;23(4):730-734. doi: 10.3748/wjg.v23.i4.730.

15.

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bottomley A, Kotapati S, de Pril V, Testori A, Eggermont AM.

Lancet Oncol. 2017 Mar;18(3):393-403. doi: 10.1016/S1470-2045(17)30015-3. Epub 2017 Feb 3.

16.

Ipilimumab Adjuvant Therapy in Melanoma.

Eggermont AMM, Suciu S, Testori A.

N Engl J Med. 2017 Jan 26;376(4):399. doi: 10.1056/NEJMc1615564. No abstract available.

17.

Physician migration at its roots: a study on the emigration preferences and plans among medical students in Romania.

Suciu ŞM, Popescu CA, Ciumageanu MD, Buzoianu AD.

Hum Resour Health. 2017 Jan 19;15(1):6. doi: 10.1186/s12960-017-0181-8.

18.

New pharmacological strategies in rheumatic diseases.

Schiotis RE, Buzoianu AD, Mureșanu DF, Suciu S.

J Med Life. 2016 Jul-Sep;9(3):227-234. Review.

19.

Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).

Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H, Wijermans PW, Suciu S, Bissé E, Claus R.

Br J Haematol. 2017 Feb;176(4):609-617. doi: 10.1111/bjh.14463. Epub 2016 Dec 1.

PMID:
27905102
20.

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F.

Haematologica. 2017 Feb;102(2):e47-e51. doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27. No abstract available.

21.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A.

N Engl J Med. 2016 Nov 10;375(19):1845-1855. Epub 2016 Oct 7.

22.

Arl13b regulates Shh signaling from both inside and outside the cilium.

Mariani LE, Bijlsma MF, Ivanova AI, Suciu SK, Kahn RA, Caspary T.

Mol Biol Cell. 2016 Sep 28. pii: mbc.E16-03-0189. [Epub ahead of print] Erratum in: Mol Biol Cell. 2017 Apr 1;28(7):996.

23.

Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy.

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Sacré L, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2016 Nov;67:38-45. doi: 10.1016/j.ejca.2016.07.020. Epub 2016 Sep 2. Erratum in: Eur J Cancer. 2017 Sep;82:247.

PMID:
27592070
24.

Credibility judgments in web page design - a brief review.

Selejan O, Muresanu DF, Popa L, Muresanu-Oloeriu I, Iudean D, Buzoianu A, Suciu S.

J Med Life. 2016 Apr-Jun;9(2):115-9. Review.

25.

Gait analysis and functional outcomes after twelve-week rehabilitation in patients with surgically treated ankle fractures.

Suciu O, Onofrei RR, Totorean AD, Suciu SC, Amaricai EC.

Gait Posture. 2016 Sep;49:184-189. doi: 10.1016/j.gaitpost.2016.07.006. Epub 2016 Jul 7.

PMID:
27434488
26.

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.

Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group.

Melanoma Res. 2016 Aug;26(4):367-76. doi: 10.1097/CMR.0000000000000237.

PMID:
27076041
27.

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F.

J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.

PMID:
26811524
28.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.

Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.

PMID:
26790144
29.

Melanoma burden by melanoma stage: Assessment through a disease transition model.

Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, Francart J, Calay F, Haagsma JA, Baurain JF, Thomas L, Beutels P, Speybroeck N.

Eur J Cancer. 2016 Jan;53:33-41. doi: 10.1016/j.ejca.2015.09.016. Epub 2015 Dec 13.

PMID:
26693897
30.

Comparative animal study of the antinociceptive efficacy of lamotrigine and gabapentin for the management of pain.

Szabo AZ, Bocsan IC, Suciu S, Buzoianu AD.

Acta Physiol Hung. 2015 Dec;102(4):363-71. doi: 10.1556/036.102.2015.4.3.

PMID:
26690028
31.

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.

Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.

Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.

PMID:
26596971
32.

Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials.

Simon P, Suciu S, Clappier E, Cave H, Sirvent N, Plat G, Thyss A, Mechinaud F, Costa VM, Ferster A, Lutz P, Mazingue F, Plantaz D, Plouvier E, Bertrand Y, Benoit Y, Dastugue N, Rohrlich PS; Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC).

Ann Hematol. 2016 Jan;95(1):93-103. doi: 10.1007/s00277-015-2515-8. Epub 2015 Oct 12.

PMID:
26455579
33.

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).

de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, Amadori S, Willemze R, Muus P, Baron F.

Ann Hematol. 2015 Dec;94(12):1981-9. doi: 10.1007/s00277-015-2486-9. Epub 2015 Sep 26.

34.

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).

Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.

Ann Hematol. 2015 Dec;94(12):2003-13. doi: 10.1007/s00277-015-2489-6. Epub 2015 Sep 24.

PMID:
26400023
35.

CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.

Ghazavi F, Clappier E, Lammens T, Suciu S, Caye A, Zegrari S, Bakkus M, Grardel N, Benoit Y, Bertrand Y, Minckes O, Costa V, Ferster A, Mazingue F, Plat G, Plouvier E, Poirée M, Uyttebroeck A, van der Werff-Ten Bosch J, Yakouben K, Helsmoortel H, Meul M, Van Roy N, Philippé J, Speleman F, Cavé H, Van Vlierberghe P, De Moerloose B.

Haematologica. 2015 Oct;100(10):1311-9. doi: 10.3324/haematol.2015.126953. Epub 2015 Jul 2.

36.

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P, Caye A, Vivent J, Costa V, Ferster A, Lutz P, Mazingue F, Millot F, Plantaz D, Plat G, Plouvier E, Poirée M, Sirvent N, Uyttebroeck A, Yakouben K, Girard S, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Cavé H; European Organisation for Research and Treatment of Cancer, Children's Leukemia Group (EORTC-CLG).

Leukemia. 2015 Nov;29(11):2154-61. doi: 10.1038/leu.2015.134. Epub 2015 Jun 8.

PMID:
26050650
37.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A.

Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262. Lancet Oncol. 2016 Jun;17 (6):e223.

PMID:
25840693
38.

First year medical students' attitude toward anatomical corpse dissection and its relationship with their personality.

Bob MH, Popescu CA, Suciu ŞM, Buzoianu AD.

Rom J Morphol Embryol. 2015;56(1):321-4.

39.

Mobilisation of blubber fatty acids of northern elephant seal pups (Mirounga angustirostris) during the post-weaning fast.

Louis C, Perdaens L, Suciu S, Tavoni SK, Crocker DE, Debier C.

Comp Biochem Physiol A Mol Integr Physiol. 2015 May;183:78-86. doi: 10.1016/j.cbpa.2015.01.008. Epub 2015 Jan 23.

PMID:
25622775
40.

Ethical views, attitudes and reactions of Romanian medical students to the dissecting room.

Bob MH, Popescu CA, Armean MS, Suciu SM, Buzoianu AD.

Rev Med Chir Soc Med Nat Iasi. 2014 Oct-Dec;118(4):1078-85.

PMID:
25581973
41.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Hengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T.

Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.

PMID:
25402418
42.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.

Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T.

Ann Hematol. 2015 Jan;94(1):23-34. doi: 10.1007/s00277-014-2177-y. Epub 2014 Aug 7.

PMID:
25096636
43.

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH.

Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. Epub 2014 Mar 29.

PMID:
24994606
44.

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.

Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, Boezeman JB, Marie JP, Halkes CJ, de Witte T, Huls G, Suciu S, Wevers RA, van der Reijden BA, Jansen JH; EORTC Leukemia Group and GIMEMA.

Blood. 2014 Aug 14;124(7):1110-8. doi: 10.1182/blood-2013-08-518514. Epub 2014 Jul 1.

45.

Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.

Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A, Uyttebroeck A, Sirvent N, Lutz P, Yakouben K, Munzer M, Röhrlich P, Plantaz D, Millot F, Philippet P, Dastugue N, Girard S, Cavé H, Benoit Y, Bertrandfor Y; Children's Leukemia Group (CLG) of European Organisation for Research and Treatment of Cancer (EORTC).

Haematologica. 2014 Jul;99(7):1220-7. doi: 10.3324/haematol.2014.103507. Epub 2014 Apr 11.

46.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF.

Bone Marrow Transplant. 2014 Jul;49(7):865-72. doi: 10.1038/bmt.2014.39. Epub 2014 Mar 31. Review.

PMID:
24686988
48.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.

Ann Oncol. 2014 Mar;25(3):742-6. doi: 10.1093/annonc/mdt585. Epub 2014 Feb 7.

49.

Increased chemerin and decreased omentin-1 levels in morbidly obese patients are correlated with insulin resistance, oxidative stress and chronic inflammation.

Cătoi AF, Suciu Ş, Pârvu AE, Copăescu C, Galea RF, Buzoianu AD, Vereşiu IA, Cătoi C, Pop ID.

Clujul Med. 2014;87(1):19-26. doi: 10.15386/cjm.2014.8872.871.afc1. Epub 2014 Jan 30.

50.

Professor Maurice Staquet, MD, MS (1930 - 2013).

Duez N, Eeckhoudt D, Kirkpatrick A, Solbu G, Suciu S, Sylvester R, Van Glabbeke M, Buyse M, Dalesio O, Renard J, Rotmensz N.

Stat Med. 2013 Dec 30;32(30):5219-20. doi: 10.1002/sim.6034. Epub 2013 Oct 31. No abstract available.

PMID:
24302281

Supplemental Content

Support Center